GDF2 and pulmonary arterial hypertension: Therefore, double treatment with an endothelin receptor inhibitor, which is a potent inhibitor of pulmonary hypertension in the clinic and in experimental BPD (Wagenaar et al., 2013), may be considered in addition to BMP9 to improve treatment of severe (experimental) BPD.